Skip to content
Review

Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination.

Jul 2026 · Acta Pharmacologica Sinica · 0 citations · 83 references
Medicine

TL;DR

This review elaborates on the latest design optimization strategies and research advances of next-generation function-enhanced ADCs, focusing on four core directions: bispecific ADC construction, internalization efficiency improvement, binding affinity enhancement, and payload combination innovation.

View source

Similar papers

Review Open access Aug 2026

Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies

This review examines the structural and biologic features that determine clinical activity, including target selection, linker stability, payload class, drug-to-antibody ratio, tumor penetration, biomarkers, toxicity, and resistance.

A. Philipovskiy, Scott Shurmur, Muhammad Bilal Abid · 0 citations
Review Aug 2026

Bispecific Antibody-Drug Conjugates in Oncology: Design Principles, Clinical Progress, and Challenges

Contin improvements in antibody engineering, linker optimization, payload development, computational modeling, and biomarker-guided patient selection are expected to further improve the therapeutic index and translational success of bsADCs in cancer treatment.

Vaishali Verma, Nimisha Sinha, Abhishek Kasana · 0 citations
Review Jul 2026

Antibody-drug conjugates in solid tumors: Efficacy, challenges, and opportunities.

This review discusses the important components of ADC design in the context of clinical successes and failures, and evaluates mechanisms of intrinsic and acquired resistance and strategies to overcome these barriers.

N. Shah, F. Meric-Bernstam · 0 citations
Open access Jul 2026

Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy

Preclinical investigation of trastuzumab-encapsulated actinomycin D, a HER2-targeted AED, has demonstrated potent antitumor activity across cancer models with varying HER2 expression levels, alongside a favorable toxicity profile in animal models, position AED as a promising next-generation targeted cancer therapy that...

Lin-Rong Li, Armando E. Giuliano, Qiang Sun et al. · 0 citations
Review Aug 2026

Precision Warfare in Solid Tumors: Molecular Mechanisms and Emerging Frontiers of Antibody-Drug Conjugates.

Continual advances in molecular engineering and precision biomarker strategies are redefining ADCs as versatile platforms for precision oncology and may enable broader, potentially tumor-agnostic, applications in solid tumors.

H. P. Luqmana, A. Ashariati, M. Savitri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.